Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis.
The NF-kappa B/Rel family of transcription factors participates in the activation of a diverse range of genes involved in inflammation, immune response, lymphoid differentiation, growth control and development. The present review provides a brief overview of NF-kappa B/Rel activation and a detailed analysis of important biological and biochemical inhibitors of the NF-kappa B/Rel pathway. Given the pleiotropic role of NF-kappa B in controlling cytokines and other immunoregulatory genes, the inhibition of NF-kappa B activation by steroid hormones, antioxidants, protease inhibitors and other compounds may provide a pharmacological basis for interfering with pathological inflammatory conditions, cancer and AIDS.
Terry Fox Molecular Oncology Group, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
P
P
Beauparlant
J
J
Hiscott
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis* / Q000187:drug effects; D015232:Dinoprostone / Q000494:pharmacology; D005544:Forecasting; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009154:Mutation; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D020572:Oncogene Proteins v-rel; D010766:Phosphorylation / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D015682:Retroviridae Proteins, Oncogenic / Q000187:drug effects* / Q000378:metabolism*; D016559:Tacrolimus / Q000494:pharmacology; D051841:Transcription Factor RelB; D014157:Transcription Factors
D000975:Antioxidants; D016207:Cytokines; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D020572:Oncogene Proteins v-rel; D011480:Protease Inhibitors; D011518:Proto-Oncogene Proteins; C497593:RELB protein, human; D015682:Retroviridae Proteins, Oncogenic; D014157:Transcription Factors; D051841:Transcription Factor RelB; D009569:Nitric Oxide; D016572:Cyclosporine; D015232:Dinoprostone; D001241:Aspirin; D016559:Tacrolimus